<DOC>
	<DOC>NCT00149292</DOC>
	<brief_summary>Assess the efficacy of a new drug (a receptor agonist that modulates the glutamatergic activity) in the treatment of schizophrenia. The primary objective of this study is to determine if a mGlu2/3 agonist dosed for 28 days is superior to placebo in the treatment of patients with schizophrenia as measured by the Positive and Negative Symptom Scales (PANSS) total score.</brief_summary>
	<brief_title>Study of LY2140023 in Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>meet the DSMIV criteria for schizophrenia as confirmed by modified SCID meet the full syndromal criteria for other Axis I disorder have taken any depot antipsychotic within 4 weeks before screening are taking moodstabilizing agents</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2006</verification_date>
</DOC>